The position of mefloquine as a 21st century malaria chemoprophylaxis

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Schlagenhauf, Patricia ^a   Adamcova, Miriam ^b   Regep, Loredana ^b   Schaerer, Martin T ^b   Rhein, Hans Georg ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CARDIOTONIC AGENT; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; DOXYCYCLINE; MEFLOQUINE; PRIMAQUINE; SAVARIN; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT;

ANTIMALARIAL DRUG RESISTANCE; ANXIETY DISORDER; CHEMOPROPHYLAXIS; DEPRESSION; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EMOTIONAL DISORDER; HEADACHE; HUMAN; INSOMNIA; MALARIA; MENTAL DISEASE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PREGNANCY; PSYCHOSIS; REVIEW; SEIZURE; SLEEP DISORDER; VERTIGO; DRUG EFFECT; DRUG RESISTANCE; METHODOLOGY; PLASMODIUM; TRAVEL;

ANTIMALARIALS; CHEMOPREVENTION; DRUG RESISTANCE; HUMANS; MALARIA; MEFLOQUINE; PLASMODIUM; TRAVEL;

EID: 78649796783     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-357     Document Type: Review

References (75)

1. Tourism highlights 2008. World Tourism Organisation (WTO), http://unwto.org/facts/eng/pdf/highlights/UNWTO-Highlights08-en-HR.pdf
2. Imported malaria in industrialized countries. Trends and perspectives. P Muentener P Schlagenhauf R Steffen, Bull World Health Organ 1999 77 560 566 10444879
3. Multicenter EuroTravNet/GeoSentinel study of travel-related infectious diseases in Europe. P Gautret P Schlagenhauf J Gaudart F Castelli P Brouqui F von Sonnenburg L Loutan P Parola GeoSentinel Surveillance Network, Emerg Infect Dis 2009 15 1783 1790 19891866
4. Malaria risk in travelers. HH Askling J Nilsson A Tegnell R Janzon K Ekdahl, Emerg Infect Dis 2005 11 436 441 15757560
5. Migrants as a major risk group for imported malaria in European countries. P Schlagenhauf R Steffen L Loutan, J Travel Med 2003 10 106 107 10.2310/7060.2003.31764 12650653
6. Imported malaria in children in industrialized countries, 1992-2002. K Stäger F Legros G Krause N Low D Bradley M Desai S Graf S D'Amato Y Mizuno R Janzon E Petersen J Kester R Steffen P Schlagenhauf, Emerg Infect Dis 2009 15 185 191 19193261
7. Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in Papua, Indonesia. GP Maguire T Handojo MCF Pain E Kenangalem RN Price E Tjitra NM Anstey, JID 2005 192 1966 74 10.1086/497697 16267769
8. Deaths caused by malaria in Switzerland 1988-2002. D Christen R Steffen P Schlagenhauf, Am J Trop Med Hyg 2006 75 1188 1194 17172391
9. Malaria. World Health Organization, International Travel and Health WHO, Geneva 2010 http://www.who.int/ith
10. Malaria. Centers for Disease Control and Prevention (CDC), Health Information for International Travel Atlanta: US Department of Health and Human Services, Public Health Service 2010
11. P Chiodini D Hill D Lalloo G Lea E Walker C Whitty B Bannister, Guidelines for malaria prevention in travellers from the United Kingdom London, Health Protection Agency 2007 http://www.hpa.org.uk/infections/topics-az/ malaria/ACMP.htm
12. Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers. Health Canada, Canada Comm Dis Rep 2006 30 1 62 http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/04vol30/30s1/page3-e.html
13. Malariaschutz für Kurzzeitaufenthalter. C Hatz B Beck J Blum B Bourquin F Brenneke M Funk G Genton P Schlagenhauf R Steffen U Stoessl, Supplementum 1. BAG Bulletin 2006 http://www.bag.admin.ch/themen/medizin/00682/ 00684/02535/index.html?lang=fr
14. Santé des voyageurs et recommendations sanitaires 2010. Institut de Veille Sanitaire, Republique Francaise, Bulletin Epidemiologique Hebdomadaire 2010 21-22 234 241
15. R Bialek G-D Burchard T Jelinek HD Nothdurft C Schonfeld K-J Volkmer, Empfehlungen Malariavorbeugung Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG) http://www.dtg.org
16. Australian Antibiotic Guidelines, Antibiotic version 13, 2006, Therapeutic guidelines Ltd North Melbourne, Australia 2006
17. Malaria Disease Prevention Committee, Malaria Prevention Guidelines for Japanese Travelers 2005 Free Press, Tokyo 2005 1 43
18. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. P Schlagenhauf, J Travel Med 1999 6 122 133 10.1111/j.1708-8305.1999.tb00843.x 10381965
19. Antimalarial activity of mefloquine and chloroquine against blood induced Plasmodium knowlesi infection in rhesus monkeys. PP Singh GP Dutta, Indian J Med Res 1981 73 Suppl 23 28 6974694
20. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. U Bronner PC Divis A Färnert B Singh, Malar J 2009 8 15 10.1186/1475-2875-8-15 19146706
21. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. GD Shanks DM Gordon FW Klotz GM Aleman AJ Oloo D Sadie TR Scott, Clin Infect Dis 1998 27 494 499 10.1086/514710 9770146
22. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. P Schlagenhauf A Tschopp R Johnson HD Nothdurft B Beck E Schwartz M Herold B Krebs O Veit R Allwinn R Stetffen, BMJ 2003 327 1078 1081 10.1136/bmj.327.7423.1078 14604928
23. Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army. D Baudon G Martet B Pascal J Bernhard A Keundjian R Laroche, Trans R Soc Trop Med Hyg 1999 93 302 303 10.1016/S0035-9203(99)90030-5 10492765
24. Safety of doxycycline and minocycline: a systematic review. K Smith JJ Leyden, Clin Ther 2005 27 1329 42 10.1016/j.clinthera.2005.09.005 16291409
25. Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West Africa. L Widmer P Blank K Van Herck C Hatz P Schlagenhauf, BMC Infect Dis 2010 10 279 10.1186/1471-2334-10-279 20860809
26. Mefloquine resistance in Plasmodium falciparum. FP Mockenhaupt, Parasitol Today 1995 11 248 253 10.1016/0169-4758(95)80201-0 15275335
27. Long-term malaria prophylaxis with weekly mefloquine. HO Lobel M Miani T Eng KW Bernard AW Hightower CC Campbell, Lancet 1993 341 848 851 10.1016/0140-6736(93)93058-9 8096560
28. Multi-drug resistant falciparum malaria in Cameroon in 1987-1988. II Mefloquine resistance confirmed in vivo and in vitro and its correlation with quinine resistance. P Brasseur J Kouamouo R Moyou-Somo P Druilhe, Am J Trop Med Hyg 1992 46 8 14 1536387
29. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross resistance to halofantrine and quinine. AF Cowman D Galatis JK Thompson, Proc Nat Acad Sci USA 1994 91 1143 1147 10.1073/pnas.91.3.1143 8302844
30. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. MB Reed KJ Saliba SR Caruana K Kirk AF Cowman, Nature 2000 403 906 909 10.1038/35002615 10706290
31. Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria. AM Oduola GO Omitowoju L Gerena DE Kyle WK Milhous A Sowunmi LA Salako, Trans R Soc Trop Med Hyg 1993 87 81 83 10.1016/0035-9203(93)90434-R 8465407
32. Use of mefloquine chemoprophylaxis by non-immune travelers before and during pregnancy. A critical evaluation of the evidence from 1985-2005. P Schlagenhauf M Boutros Suarez T Leuenberger E Fröhlich, Abstract NECTM Edinburgh 2006
33. Malaria in pregnancy and the newborn. S Rogerson, Adv Exp Med Biol 2010 659 139 152 full-text 20204762
34. G Briggs R Freeman S Yaffe, A reference guide to fetal and neonatal risk. Drugs in pregnancy and lactation Lippincott Williams & Wilkins. Philadelphia 7 2005
35. Safety, efficacy and determinants of the effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum endemic sub-Saharan Africa. RD Newman ME Parise L Slutsker B Nahlen RW Steketee, Trop Med Internat Health 2003 6 488 506 10.1046/j.1365-3156.2003. 01066.x
36. Drugs for treating uncomplicated malaria in pregnant women. L Orton P Garner, Cochrane Database of Systematic Reviews 2005 3 D004912.pub2
37. Postmarketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. B Vanhauwere H Maradit L Kerr, Am J Trop Med Hyg 1998 58 17 21 9452285
38. Principles and practice of teratology for the obstetrician. B Fisher NC Rose JC Carey, Clin Obstet Gynecol 2008 51 106 118 10.1097/GRF.0b013e318161d2c8 18303504
39. Stereoselective pharmacokinetics of mefloquine in young children. A Bourahla C Martin F Gimenez V Singhasivanon P Attanath A Sabchearon T Chongsuphajaisiddhi R Farinotti, Eur J Clin Pharmacol 1996 50 241 244 10.1007/s002280050100 8737767
40. Mefloquine in infants and young children. C Luxemburger RN Price F Nosten FO Ter Kuile T Chongsuphajaisiddhi NJ White, Ann Trop Paediatr 1996 16 281 286 8985524
41. Prevention of malaria in long-term travelers. L Chen ME Wilson P Schlagenhauf, JAMA 2006 296 2234 2244 10.1001/jama.296.18.2234 17090770
42. Long-term malaria prophylaxis for travelers. J Knobloch, J Travel Med 2004 11 374 378 10.2310/7060.2004.19207 15569575
43. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travellers to malaria endemic countries. D Overbosch, J Travel Med 2003 10 Suppl 1 16 20 12737756
44. The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of Plasmodium falciparum malaria non-immune travellers and expatriates. PJ van Genderen HR Koene K Spong D Overbosch, J Travel Med 2007 14 92 95 10.1111/j.1708-8305.2007.00116.x 17367478
45. The safety of atovaquone/proguanil in long-term prophylaxis of nonimmune adults. E Petersen, J Travel Med 2003 10 Suppl 1 13 15
46. Steady state pharmacokinetics of mefloquine in long-term travellers. RA Pennie G Koren C Crevoisier, Trans R Soc Trop Med Hyg 1993 87 459 462 10.1016/0035-9203(93)90036-P 8249080
47. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. A Sonmez A Harlak S Kilic Z Polat L Hayat O Keskin T Dogru MI Yilmaz CH Acikel IH Kocar, J Infect 2005 51 253 258 10.1016/j.jinf.2005.01.014 16230223
48. Mefloquine use and hospitalizations among US service members, 2002-2004. TS Wells TC Smith B Smith LZ Wang CJ Hansen RJ Reed WE Goldfinger TE Corbeil CN Spooner MA Ryan, Am J Trop Med Hyg 2006 74 744 749 16687673
49. Controversies and misconceptions in malaria chemoprophylaxis for travelers. LH Chen ME Wilson P Schlagenhauf, JAMA 2007 297 2251 2263 10.1001/jama.297.20.2251 17519415
50. Malaria prophylaxis in different age groups. ML Mittelholzer M Wall R Steffen D Stürchler, J Travel Med 1996 4 219 223 10.1111/j.1708-8305.1996. tb00750.x
51. Tolerability and effectiveness of malaria chemoprophylaxis with mefloquine or chloroquine with or without co-medication. JC Handschin M Wall R Steffen D Stürchler, J Travel Med 1997 4 121 127 10.1111/j.1708-8305.1997. tb00798.x 9815496
52. Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study. C Crevoisier I Joseph M Fischer H Graf, Antimicrob Agents Chemother 1995 39 1892 1895 7486943
53. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. AL Aarnoudse RH van Schaik J Dieleman M Molokhia MM van Riemsdijk RJ Ligthelm D Overbosch IP van der Heiden BH Stricker, Clin Pharmacol Ther 2006 80 367 374 10.1016/j.clpt.2006.07.003 17015054
54. Evaluation of mood profiles during malaria chemoprophylaxis. A randomized, double-blind, four-arm study. P Schlagenhauf R Johnson E Schwartz HD Nothdurft R Steffen, J Travel Med 2009 16 42 45 10.1111/j.1708-8305.2008.00272. x 19192127
55. Prevention and morbidity in non-immune subjects; a case-control study among Italian troops in Somalia and Mozambique, 1992-1994. MS Pergallo G Sabatinelli G Majori G Cali G Sarnicola, Trans R Soc Trop Med Hyg 1997 91 343 346 10.1016/S0035-9203(97)90101-2 9231213
56. Drugs for preventing malaria in travellers. FA Jacquerioz AM Croft, The Cochrane Collaboration 2009 4
57. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. R Steffen E Fuchs J Schildknecht U Naef M Funk P Schlagenhauf P Phillips-Howard C Nevill D Stürchler, Lancet 1993 341 1299 1303 10.1016/0140-6736(93)90814-W 8098447
58. Comparasion of adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. PJ Barrett PD Emmins PD Clarke DJ Bradley, BMJ 1996 313 525 528 8789977
59. Atovaquone/proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. D Overbosch HS Schilthuis U Bienzle RH Behrens KC Kain PD Clarke S Toovey J Knobloch HD Nothdurft NS Roskell JD Chulay, Clin Infect Dis 2001 33 1015 1021 10.1086/322694 11528574
60. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. CR Meier K Wilcock SS Jick, Drug Safety 2004 27 203 213 10.2165/00002018-200427030-00005 14756582
61. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. MA Phillips RB Kass, J Travel Med 1996 3 40 45 10.1111/j.1708-8305.1996.tb00695.x 9815421
62. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. P Schlagenhauf R Steffen H Lobel R Johnson R Letz A Tschopp N Vranjes Y Bergqvist O Ericsson U Hellgren L Rombo S Mannino J Handschin D Stürchler, Trop Med Int Health 1996 1 485 494 10.1046/j.1365-3156.1996.d01-85.x 8765456
63. Sex, gender and travel associated disease. P Schlagenhauf LH Chen ME Wilson DO Freedman D Tcheng E Schwartz P Pandey R Weber D Nadal C Berger F von Sonnenburg J Keystone K Leder, Clin Infect Dis 2010 50 826 832 10.1086/650575 20156059
64. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults; results of a questionnaire-based study. L Ollivier K Tifratene R Josse A Keundjian JP Boutin, Ann Trop Med Parasitol 2004 6 639 641 10.1179/000349804225021262
65. Mefloquine neurotoxicity: a literature review. S Toovey, Travel Med Infect Dis 2009 7 2 6 10.1016/j.tmaid.2008.12.004 19174293
66. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. SJ Cruikshank M Hopperstad M Younger BW Connors DC Spray M Srinivas, Proc Natl Acad Sci USA 2004 101 12364 12369 10.1073/pnas.0402044101 15297615
67. Excitatory effects of gap junction blockers on cerebral cortex seizure-like activity in rats and mice. LJ Voss G Jacobson JW Sleigh A Steyn-Ross M Steyn-Ross, Epilepsia 2009 50 1971 1978 10.1111/j.1528-1167.2009. 02087.x 19486358
68. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. YT Pham F Nosten R Farinotti NJ White F Gimenez, Int J Clin Pharmacol Ther 1999 37 58 61 Erratum in: Int J Clin Pharmacol Ther 1999, 37 : 316. 10027484
69. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses. F Gimenez RA Pennie G Koren C Crevoisier IW Wainer R Farinotti, J Pharm Sci 1994 83 824 827 10.1002/jps.2600830613 9120814
70. Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. U Hellgren I Berggren-Palme Y Bergqvist M Jerling, Br J Clin Pharmacol 1997 44 119 124 10.1046/j.1365-2125.1997.00633.x 9278194
71. Sex-dependent gene regulatory networks of the heart rhythm. DA Iacobas S Iacobas N Thomas DC Spray, Funct Integr Genomics 2010 10 73 86 10.1007/s10142-009-0137-8 19756788
72. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. C Ohrt Tl Ritchie H Widjaja GD Shanks J Fitriadi DJ Fryauff J Handschin D Tang B Sandjaja E Tjitra L Hadiarso G Watt FS Wignall, Ann Intern Med 1997 126 963 972 9182474
73. Tolerability of prophylactic Lariam regimens. E Boudreau B Schuster J Sanchez GD Shanks J Fitriadi DJ Fryauff J Handschin D Tang B Sandjaja E Tjitra L Hadiarso G Watt FS Wignall, Trop Med Parasit 1993 44 257 265
74. Adverse reactions to mefloquine associated with ethanol ingestion. RC Wittes R Sagmur, Can Med Assoc J 1995 152 515 517
75. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. RL Nevin, Pharmacoepidemiol Drug Safety 2010 19 206 210 10.1002/pds.1879